An estimated 20-25 percent of the world's population has a fungal infection, which is most commonly a Trichophyton type of infection, making fungal disease infection one of the most common types of infection worldwide. Due to drug resistance and changes in the morphology of the fungi, treating fungal infections in humans is one of the most difficult cases to cure. Since 1960, the discovery of systemic antifungal chemotherapy has made a substantial contribution to the treatment of the majority of human fungal infections. Antifungal agents' chemotherapy rely completely on their ability to disrupt the integrity of the plasma membrane, cell wall, cell metabolism, mitotic activity, or inhibit fungal cell formation. Topically (to treat local infections) or systemically (to heal skin infections) antifungal treatments are available (systemic infections treatment). Structure, solubility, mode of action, pharmacokinetics, activity spectrum, therapeutic impact (fungicidal or fungistatic), and toxicity are all characteristics of antifungal medicines. The emerging of multi-drug-resistant fungal diseases has given rise to a new class of fungal infections. The availability of medications that target fungal cells rather than human cells further restricts pharmaceutical options for treating fungal infections. A brief systematic overview of the types of fungal infections, characteristics of antifungal medicines, and the future of antifungal therapy has been clearly stated in the current review so that it can be utilised in further upcoming study.
Cite this article:
Amitder Nath Chatterjee. Role of Antifungal Therapy in Treating different Types of Fungal Infections and it’s Future: A Systematic Review. Asian Journal of Pharmaceutical Research. 2023; 13(2):129-5. doi: 10.52711/2231-5691.2023.00026
Amitder Nath Chatterjee. Role of Antifungal Therapy in Treating different Types of Fungal Infections and it’s Future: A Systematic Review. Asian Journal of Pharmaceutical Research. 2023; 13(2):129-5. doi: 10.52711/2231-5691.2023.00026 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2023-13-2-12
1. Richardson MD, Warnock DW. Fungal infection: diagnosis and management. John Wiley and Sons; 2012 Jan 5.
2. Basak A, Chakraborty R, Mandal SM, editors. Recent trends in antifungal agents and antifungal therapy. New Delhi, India: Springer; 2016 Sep 21.
3. Souto EB, Wissing SA, Barbosa CM et al (2004) Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 278(1):71–77.
4. Bachhav YG, Mondon K, Kalia YN et al (2011) Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. J Control Release. 153 (2):126–132.
5. Che J, Wu Z, Shao W et al (2015) Synergetic skin targeting effect of hydroxypropyl-β-cyclodextrin combined with microemulsion for ketoconazole. Eur J Pharm Biopharm. doi:10.1016/j.ejpb.2015.03.028.
6. Guo F, Wang J, Ma M et al (2015) Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med. doi:10.1007/s10856-015-5487-2.
7. Alomrani AH, Shazly GA, Amara AA, Badran MM (2014) Itraconazole-hydroxypropyl-β-cyclodextrin loaded deformable liposomes: in vitro skin penetration studies and antifungal efficacy using Candida albicans as model. Colloids Surf B. 121:74–81.
8. C¸ elebi N, Ermis¸ S, O¨ zkan S (2015) Development of topical hydrogels of terbinafine hydrochloride and evaluation of their antifungal activity. Drug Dev Ind Pharm. 41(4):631–639.
9. Randhawa MA, Gondal MA, Al-Zahrani AH et al (2015) Synthesis, morphology and antifungal activity of nano-particulated amphotericin-B, ketoconazole and thymoquinone against Candida albicans yeasts and Candida biofilm. J Environ Sci Health Part A Toxic Hazard Subst Environ Eng. 50(2):119–124.
10. Melkoumov A, Goupil M, Louhichi F et al (2015) Nystatin nanosizing enhances in vitro and in vivo antifungal activity against Candida albicans. J Antimicrob Chemother. doi:10.1093/jac/dkt137.
11. Arya Yesudas, Awasthy Babu, Athira Anil, Athira S, Brincy Thomas, Feby Fulgen. A Descriptive Study to assess the knowledge regarding Fungal infections among adolescent girls in selected areas of Kollam. Asian Journal of Nursing Education and Research. 2022; 12(2):239-1.
12. Rakesh Kumar Joshi. Chemical Constituents of Artemisia nilagirica (Clarke) from Western Himalaya of Uttrakhand, India. Asian J. Pharm. Ana. 2020; 10(4):182-184.
13. S.D. Mankar, Waditake Poonam, Prajakta Jejurkar. Review on Mucormycosis: It is a life Threatening infection. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(4):316-8.
14. Rakesh K. Joshi, Bipin C. Joshi, Mukul K. Sati. Chemical and Chemotaxonomic Aspects of Some Aromatic and Medicinal Plants Species from Utrrakhand: Asian J. Pharm. Tech. 2014; Vol. 4: Issue 3, Pg 157-162.
15. Monika Gupta, Aditi Gupta, Sudhakar Gupta. Insecticidal Activity of Essential Oils Obtained from Piper nigrum and Psoralea corylifolia Seeds against Agricultural Pests. Asian J. Research Chem. 6(4): April 2013; Page 360-363.
16. Prajwali Bhalerao, Dattaprasad N. Vikhe, Ravindra S. Jadhav. Mucormycosis. Research Journal of Pharmacognosy and Phytochemistry. 2022; 14(2):73-6.
17. Ananta Choudhury, Suman Saha, Sanjib Bahadur, Amit Roy. Synergistic Antifungal Activity of Bioactive Phytochemical in Combination with Standard Antifungal Drugs. Research J. Pharm. And Tech. 2019; 12(5):2346-2352.
18. Shweta Shriwas, Raju Chouksey, Sumeet Dwivedi. Anti-Candida activity of few India Medicinal herbs used in the treatment of Gynecological disorders. Research Journal of Pharmacy and Technology. 2021; 14(4):2185-7.
19. B. Usharani. Extraction of Essential oils from Cymbopogon citratus using Organic solvents. Research Journal of Pharmacy and Technology. 2021; 14(11):5709-2.
20. B. R. Malathy, Sweetlin Ajitha P, Sangeetha K. S, Swetha Thampy, Kamala G. Antimicrobial activity of Commercial essential oil on human pathogens. Research Journal of Pharmacy and Technology. 2021; 14(8):4440-4.